AXIM Biotech recently announced it would begin a series of clinical trials of its patented cannabinoid controlled-release chewing gum. The trials for MedChew RX gum, which contains 5 milligrams of cannabidiol, a non-psychoactive component of cannabis, and 5 milligrams of THC, a psychoactive cannabinoid, will be carried out in Europe.
The biotech company hopes that the cannabis-infused chewing gum will provide a discrete, safe and effective pain-management medication for MS patients.
“Obviously the safety/efficacy issues need to be proven out by clinical trials – nonetheless, I am quite excited to see a new method for delivering effective pain medication,” said Stuart Titus, CEO of Medical Marijuana, Inc. which is invested in AXIM Biotech.
AXIM said the clinical trials are to begin in 2016, and if successful it would pursue FDA approval. The FDA has not yet approved any product containing cannabis.